Home/Hedge Fund Intelligence/Avoro Life Sciences Fund
Hedge FundDelawareMaster fund3(c)(7) · qualified purchasers

Avoro Life Sciences Fund

Estimated returns, assets and SEC record

Managed by Avoro Capital Advisors LLC · New York · in Form ADV since 2012

Avoro Life Sciences Fund is a Delaware hedge fund managed by Avoro Capital Advisors LLC. It reported gross assets of USD 8.6bn in the Form ADV filed 4 June 2024. Hedge funds do not file their returns with the SEC. From what this fund and its manager do file, PPLI Vortex estimates that it returned about 41.6% in 2025, with a likely range of 18.3% to 64.9%.

Unqualified audit opinionIndependent administratorPCAOB-registered auditor
2025, estimated+41.6%range 18.3% to 64.9% · grade D-13F · estimated for the manager as a whole
Three years, a year+22.3%2023 to 2025, compounded from the yearly estimates and their ranges
Latest quarter+12.5%to 30 Jun 2026 · range 0.5% to 23.8%
Gross assetsUSD 8.6bnForm ADV · filed 4 Jun 2024
Minimum investmentUSD 1mForm ADV, Schedule D
Investors405beneficial owners

Compiled by PPLI Vortex from SEC filings · Hedge Fund Intelligence, PPLI.com · updated · about PPLI Vortex

Return figures are PPLI.com estimates from public SEC filings, not numbers reported by the fund. Not investment advice. Important information

PPLI.com
Hedge Fund Rating
Rating in preparation
We publish a rating only once a fund's file has been through editorial review. This fund is in the queue.
Returns
Risk
SEC record and governance
Fees and terms
Fit for a PPLI policy
Editorial assessment from SEC filings
Reviewed every quarter
About the rating
D
Confidence grade D-13F

We rebuild the manager's long positions from Form 13F and scale them to how hedge funds of this kind have behaved. Shorts, leverage and fees are not visible.

How the grades work

A and B are computed from public filings. C, C-est and D-est are estimates built on what registered funds that hold the fund report. D-13F is an estimate from the manager's 13F long book. Every figure on this page is shown with its range and grade.

Quarter by quarter

Avoro Life Sciences Fund, one quarter at a time

How the estimate moved through each year since 2021, with the yearly figure alongside.

Each cell is our estimate for that quarter, with the range it could fall in underneath. The last column is the figure for the full year. It is worked out on its own from the year's filings, so the four quarters will not multiply out to it exactly. Every figure here is graded D-13F and D-est.

YearJan to MarApr to JunJul to SepOct to DecFull year
2026−0.1%-9.5% to 15.9%+12.5%0.5% to 23.8%not yet filednot yet filed+16.9%-6.4% to 40.2%, to 30 Jun
2025−5.7%-14.5% to 9.8%−3.6%-14.4% to 13.8%+19.7%8.1% to 31.4%+14.9%3.2% to 26.5%+41.6%18.3% to 64.9%
2024+8.0%-3.7% to 19.6%+0.5%-11.1% to 12.2%+3.6%-8.0% to 15.3%+1.0%-10.7% to 12.6%+16.7%-6.6% to 40.0%
2023+0.4%-11.3% to 12.0%+4.5%-7.1% to 16.2%+1.0%-10.7% to 12.6%+9.6%-2.0% to 21.3%+10.6%-12.7% to 33.9%
2022−4.7%-16.3% to 7.0%−1.0%-12.7% to 10.6%+5.1%-6.5% to 16.8%+10.4%-1.2% to 22.1%+8.6%-14.7% to 31.9%
2021−4.9%-16.5% to 6.8%+0.4%-11.2% to 12.1%+4.7%-6.9% to 16.4%+2.8%-8.8% to 14.5%+0.6%-22.7% to 23.8%

Estimates by PPLI Vortex from public SEC filings, not figures reported by the fund. n/a means the filings do not support a figure for that quarter.

Next: what the manager holds
Holdings

26 positions, with 79% of the money in the ten largest

Avoro Life Sciences Fund does not publish what it owns. Its manager does: every quarter Avoro Capital Advisors LLC lists its U.S.-listed stocks and options on Form 13F. The list covers every account the firm runs, not this fund alone, and leaves out short positions, bonds, swaps and shares listed outside the United States. Most of what the firm's hedge funds hold is in this book, so it is a fair picture of the fund.

Value reportedUSD 11.1bn
Positions26
In the ten largest79%
Largest positionUNITED THERAPEUTICS Corp, 13.5%
Holdings as of30 June 2026
The 15 largest positions

Share is of the total value reported. Options are shown at the value of the shares they cover. Choose a company to see which other managers report it.

#CompanyValueShare of the book
1 Nasdaq: UTHRHeld by 57 of the 720 managers we trackUSD 1.5bn13.5%
2 Nasdaq: ASNDOrdinary SharesHeld by 36 of the 720 managers we trackUSD 1.4bn12.2%
3 Nasdaq: KRYSHeld by 21 of the 720 managers we trackUSD 1.1bn9.6%
4 Nasdaq: MDGLHeld by 48 of the 720 managers we trackUSD 984m8.8%
5 Nasdaq: ARGXADRHeld by 35 of the 720 managers we trackUSD 928m8.3%
6 Nasdaq: ARWRHeld by 37 of the 720 managers we trackUSD 926m8.3%
7 Nasdaq: KYMRHeld by 29 of the 720 managers we trackUSD 857m7.7%
8 Nasdaq: RVMDHeld by 69 of the 720 managers we trackUSD 430m3.9%
9 Nasdaq: CYTKHeld by 57 of the 720 managers we trackUSD 426m3.8%
10 Nasdaq: CELCHeld by 29 of the 720 managers we trackUSD 356m3.2%
11 Nasdaq: GPCRADSHeld by 38 of the 720 managers we trackUSD 352m3.2%
12 Nasdaq: XENEHeld by 45 of the 720 managers we trackUSD 349m3.1%
13 Nasdaq: DFTXHeld by 49 of the 720 managers we trackUSD 338m3.0%
14 Nasdaq: QUREHeld by 45 of the 720 managers we trackUSD 310m2.8%
15 Nasdaq: VERAHeld by 38 of the 720 managers we trackUSD 246m2.2%
UNITED THERAPEUTICS Corp: 13.5%Ascendis Pharma A/S: 12.2%Krystal Biotech, Inc.: 9.6%Madrigal Pharmaceuticals, Inc.: 8.8%Argenx Se: 8.3%Arrowhead Pharmaceuticals, Inc.: 8.3%Kymera Therapeutics, Inc.: 7.7%Revolution Medicines, Inc.: 3.9%Positions 9 to 15: 21.3%The rest of the book: 6.2%26POSITIONS
How the book is split
  • UNITED THERAPEUTICS Corp13.5%
  • Ascendis Pharma A/S12.2%
  • Krystal Biotech, Inc.9.6%
  • Madrigal Pharmaceuticals, Inc.8.8%
  • Argenx Se8.3%
  • Arrowhead Pharmaceuticals, Inc.8.3%
  • Kymera Therapeutics, Inc.7.7%
  • Revolution Medicines, Inc.3.9%
  • Positions 9 to 1521.3%
  • The rest of the book6.2%
Next: returns year by year
Returns year by year

Ahead of the S&P 500 in 2025, even at the low end of our range

The SEC filings of Avoro Life Sciences Fund carry no return figures. These are our estimates, each with the range we think the true figure falls in and a grade for how it was reached.

Gold bars are the fund. The thin line on each bar is the range we think the true figure falls in. Grey bars are the S&P 500 total return in U.S. dollars, dividends reinvested, over the same calendar years. It is there as a picture of the market, not as the benchmark this fund sets itself.

-20%0%20%40%60%20210.6%20228.6%202310.6%202416.7%202541.6%2026 to date16.9%
PeriodReturnLikely rangeGradeS&P 500Difference
20210.6%-22.7% to 23.8%D-13F28.7%-28.2 pts
20228.6%-14.7% to 31.9%D-13F-18.1%+26.7 pts
202310.6%-12.7% to 33.9%D-13F26.3%-15.7 pts
202416.7%-6.6% to 40.0%D-13F25.0%-8.3 pts
202541.6%18.3% to 64.9%D-13F17.9%+23.7 pts
2026 to 30 Jun16.9%-6.4% to 40.2%D-13F

The estimate is built from the manager's whole 13F long book. We attach it to this fund as the largest hedge fund Avoro Capital Advisors LLC runs.

Returns are before the fees an investor pays unless they come from a public holder's reported value, which is after the fund's own fees.

USD 100 in Avoro Life Sciences Fund against the S&P 500start of 2021 = 100

The gold line compounds our yearly figures. The shaded area is where the line would run if every year came in at the low or the high end of its range. The grey line is the S&P 500 with dividends.

100200300400500StartEnd 2021End 2022End 2023End 2024End 2025Fund 200S&P 500 196

By the end of 2025, USD 100 in the fund had become about USD 200 by our estimate, against USD 196 in the index.

What an investor would have kept, 2021 to 2025

Takes our yearly figures for Avoro Life Sciences Fund and shows what is left after fees and tax, next to the same money inside a PPLI policy. Change any of the numbers. Our 13F-based figures price the manager's long book and take no fees off, so the tool treats them as before fees. Public filings do not settle that, and they do not give the fund's terms either. The fees are yours to set; put both at 0 to read the estimate as if it were already after fees.

Avoro Life Sciences Fund, as estimatedour yearly figures compounded, before fees and taxUSD 2m
After the fund's feeswith the fees you entered, charged above a high-water markUSD 1.7m
After tax, held directlygains taxed every year at the rate you enteredUSD 1.4m
Held inside a PPLI policyno yearly tax on gains inside a policy that keeps to the rules, less the yearly policy costUSD 1.6m
S&P 500 with dividendsthe index over the same years, before taxUSD 2m
Each year: as estimated, after fees, after tax and inside a policy
YearAs estimatedAfter feesAfter taxInside a policyS&P 500
20210.6%-0.9%-0.9%-1.9%28.7%
20228.6%5.9%3.9%4.8%-18.1%
202310.6%7.2%4.3%6.2%26.3%
202416.7%12.2%7.2%11.1%25.0%
202541.6%32.1%19.0%30.8%17.9%

The fee defaults of 1.5% and 20% are common hedge fund terms, not this fund's. The tax rate of 40.8% is the top U.S. federal rate on short-term gains with the net investment income tax; a fund whose gains are mostly long-term would be taxed at 23.8%. State tax is not included. Policy costs differ by carrier and by the size of the policy. If every year had come in at the bottom or the top of our range, the first line would read USD 636,000 or USD 5m. An illustration, not advice.

The record in numbers

Worked out from the yearly figures above, 2021 to 2025. They carry the same ranges and grades.

Annualised return14.8%
Best year41.6% in 2025
Worst year0.6% in 2021
Years ahead of the S&P 5002 of 5
Total over the period99.6%
S&P 500 over the period96.2%
Losing years0 of 5
Average width of our range47 points
Returns by period

Annualised where the period is longer than a year. The range compounds the low and high ends of each year.

PeriodAvoro Life Sciences FundLikely rangeS&P 500Difference
Latest year202541.6%18.3% to 64.9%17.9%+23.7 pts
Three years, a year2023 to 202522.3%-1.2% to 45.7%23.0%-0.7 pts
Five years, a year2021 to 202514.8%-8.6% to 38.2%14.4%+0.4 pts
Risk, as far as yearly figures show it

Measured at year ends only. A fall and recovery inside a single year does not appear here.

Deepest fall between year endsNone
S&P 500, same measure-18.1%
Losing years0 of 5
2022, side by side
Avoro Life Sciences Fund8.6%range -14.7% to 31.9%
S&P 500-18.1%with dividends

2022 was the one year in this period when the index fell. By our estimate the fund made money.

Compare with other funds

Type the name of any fund we estimate and it joins the table. Up to five at a time. Every figure is an estimate; open a fund to see its range and grade.

Fund20212022202320242025
Avoro Life Sciences Fund0.6%8.6%10.6%16.7%41.6%
S&P 500 with dividends28.7%-18.1%26.3%25.0%17.9%

Over 2023 to 2025 the estimates compound to 82.8%, or 22.3% a year.

Next: where the numbers come from
Where the numbers come from

Built from the manager's quarterly 13F filings

A hedge fund reports almost nothing about itself. Others report about it, and that is what we read.

Registered funds that hold Avoro Life Sciences Fund

Mutual funds and interval funds report every holding to the SEC on Form N-PORT. When one of them owns a stake in a hedge fund, its filings show what that stake was worth on each date.

HolderListed asReportsSeenLatest value held
A&Q Technology Fund LLCAVORO LIFE SCIENCES FUND731 Dec 2024 to 30 Jun 2026USD 12m
Avoro Capital Advisors LLC's disclosed U.S. long book

Every quarter the manager lists its U.S. listed long positions on Form 13F, most recently USD 11.1bn for 30 June 2026. Pricing those positions through each year gives the return of the long book alone. It covers all the manager's clients, not this fund, and leaves out shorts, leverage, non-U.S. holdings and fees. The long book is most of what the manager's hedge funds hold, so it says a good deal about this fund.

20212022202320242025
13F long book-11.2%0.4%14.2%9.4%57.8%
S&P 50028.7%-18.1%26.3%25.0%17.9%
-20%0%20%40%60%20212022202320242025
Next: size and investors
Size and investors

USD 8.6bn in gross assets, up from USD 12m reported in 2013

The fund in Form ADV, Schedule D

What the adviser reported about this fund in the filing of 4 June 2024. Gross assets are the fund's total assets before borrowings are deducted. They are not net assets and say nothing about performance.

Gross asset valueUSD 8.6bn
Minimum investmentUSD 1m
Beneficial owners405
Owned by the adviser and its people18%
Owned by funds of funds4%
Owned by non-U.S. persons50%
Investor eligibility3(c)(7): qualified purchasers
DomicileDelaware
StructureMaster fund
Full legal nameAvoro Life Sciences Fund LLC
SEC private fund ID805-5609721763
Gross assets over timeUSD bn, by the year the figure was filed

Each bar is the gross asset value in that year's Form ADV. An annual filing reports the previous fiscal year end, so each bar describes the year before. A change in gross assets is not a return: money coming in, money going out, borrowing and performance all move it, and the filings do not say which.

20130.020140.120150.320160.520171.320183.220192.220204.620217.220226.320237.620248.6
Master and feeder funds

Investors often enter through a feeder that passes their money to a master fund, where the trading happens.

  • Feeder: Avoro Life Sciences Offshore Fund Ltd.
Next: who audits and administers it
Service providers

Audited by KPMG, administered by Hedgeserv (Cayman), Ltd. C/O Hedgeserv Corporation

An outside auditor and an administrator that is not part of the manager are the two checks an investor can verify from public filings.

Named by the adviser in Form ADV Schedule D, questions 23 to 28, in the filing of 4 June 2024.

RoleFirmWhereAs stated in the filing
AuditorKPMGSan Francisco, CaliforniaIndependent, pcaob registered
AdministratorHedgeserv (Cayman), Ltd. C/O Hedgeserv CorporationNew York, New YorkNot related to the adviser
Prime brokerMorgan Stanley & Co. LLCNew York, New YorkAlso custodian
Prime brokerJ.P. Morgan Securities LLCNew York, New YorkAlso custodian
Prime brokerGoldman Sachs & Co. LLCNew York, New YorkAlso custodian
CustodianMorgan Stanley & Co. LLCNew York, New YorkNot related to the adviser
CustodianJ.P. Morgan Securities LLCNew York, New YorkNot related to the adviser
CustodianGoldman Sachs & Co. LLCNew York, New YorkNot related to the adviser
Audit and valuation
Audited every yearYes
Statements under U.S. GAAPYes
Audited statements sent to investorsYes
Share of assets valued by an outside party99%
General partner, manager or directors

Form ADV Schedule D, question 3.

  • Avoro Capital Advisors LLC
Next: how the fund is offered
The offering, from Form D

USD 3.5bn raised from 292 investors

A fund that sells interests privately in the United States files Form D, and amends it each year while the offering stays open.

Issuer on the filingAvoro Life Sciences Fund LLC
Total sold to dateUSD 3.5bn
Investors to date292
Minimum investmentUSD 1m
Date of first sale1 July 2010
Exemptions claimed06b, 3C, 3C.7
EntityLimited Liability Company
JurisdictionDelaware
Latest filingD/A, 1 May 2026
Form D filings on EDGAR17
People named on the Form D

Executive officers, directors and promoters of the issuer, as the filing lists them.

  • Behzad Aghazadeh Executive Officer (Portfolio Manager and Managing Partner of Avoro Capital Advisors LLC)
  • Scott Epstein Executive Officer (Partner, Chief Operating Officer & Chief Compliance Officer of Avoro Capital Advisors LLC)
  • Neil Cammarosano Executive Officer (Chief Financial Officer of Avoro Capital Advisors LLC)
Placement agents paid on the offering
  • Far Hills Group LLC
Next: the manager
The manager

Run by Avoro Capital Advisors

AdviserAvoro Capital Advisors LLC
StatusSEC-registered adviser
Registered since30 March 2012
SEC number801-74391
CRD number154091
OfficeNew York, NY
Latest Form ADV5 March 2026
Brochure (Part 2A)5 March 2026
In the manager's own words

What Avoro Capital Advisors LLC says about itself on avorocapital.com, read on 14 November 2026. A sentence in quotation marks is the firm's own; the rest is in our words. These are the firm's statements, not ours, and we have not checked them. They describe the firm as a whole, not this fund.

Founded2020
What it says it doesHealthcare and biotechnology and technology
Offices it listsNew York
People namedBehzad Aghazadeh, Managing Partner, Portfolio Manager
On the siteA team page, an investor login and a news or insights section
The manager at a glance

Gross assets are added across the funds we cover and count a master fund and its feeders separately, so they overstate the money the firm runs.

Funds of this manager on PPLI.com1
Their gross assets togetherUSD 8.6bn
With return figures1
U.S. long book on Form 13FUSD 11.1bn
Positions in that book26
Form ADV filings that list this fund25
The paper trail

Dates taken from the filings themselves.

  • 1 Jul 2010 First sale of interests, as stated on Form D
  • 22 Feb 2012 First Form ADV in the SEC's bulk data to list the fund
  • 30 Mar 2012 Avoro Capital Advisors LLC registered with the SEC
  • 4 Jun 2024 Latest Form ADV listing the fund in the bulk data
  • 31 Dec 2024 First appears as a holding of a registered fund
  • 5 Mar 2026 Latest Form ADV of the manager
  • 1 May 2026 Latest Form D
  • 14 Aug 2026 Latest Form 13F of the manager, for 30 June 2026
Next: holding it inside a policy
Inside a policy

Can Avoro Life Sciences Fund be held inside a PPLI policy?

Not directly, for a U.S. taxpayer. U.S. tax rules test what a policy holds for diversification, and a fund that is also sold to investors outside insurance accounts counts as a single holding and is not looked through to what it owns. Choosing such a fund yourself also raises the investor-control question the IRS has ruled on.

In practice a U.S.-compliant policy reaches a hedge fund strategy through an insurance-dedicated fund, whose interests are held by insurers' separate accounts with a few exceptions the regulations allow, or through a separately managed account run for the insurer. Policies issued outside the United States for people who are not U.S. taxpayers follow the rules of their own jurisdiction, and those differ.

Some managers run an insurance-dedicated version of their strategy. Where they do, gains that a taxable investor would pay tax on each year can build up inside the policy, as long as the policy keeps to the rules. We have no record that Avoro Capital Advisors LLC offers one. That is a gap in our file, not a finding that it does not. We keep a directory of insurance-dedicated funds and the managers behind them.

Insurance-dedicated funds on PPLI.com   Hedge fund strategies inside PPLI

The diversification test, on the manager's reported book

The investments inside a policy must be spread: no more than 55% in one holding, 70% in two, 80% in three and 90% in four. This table runs that test on the positions Avoro Capital Advisors LLC reported on Form 13F for 30 June 2026. It is a rough guide only, since an insurance-dedicated version would hold the whole strategy, shorts included.

MeasureLimitThis bookResult
The largest holding55%14%Within the limit
The two largest70%26%Within the limit
The three largest80%35%Within the limit
The four largest90%44%Within the limit

On this evidence the long book is spread widely enough.

Next: notes on this file
Notes

What the filings leave open

What we would ask the manager

Questions the filings raise and cannot answer.

  • 99% of the assets are valued by an outside party. Who values the rest, and how often is that tested?
  • Ten positions make up 79% of the book you report. What is the largest loss you would accept on any one of them?
  • Our estimate rests on your long book alone. What did the short book, leverage and trading inside the quarter add or take away?
  • Do you offer this strategy as an insurance-dedicated fund or a separately managed account for insurers?
Changes to this file
  • 13 Nov 2026 File opened from SEC filings
  • 14 Nov 2026 Manager's website read and its facts added
  • 15 Nov 2026 Page revised.
The manager's response

Not yet received. Avoro Capital Advisors LLC can ask us to check any fact on this page and can send a response, which we will publish here unedited. Write to the editor.

Next: questions
Questions

Questions about Avoro Life Sciences Fund

What has Avoro Life Sciences Fund returned?

The SEC filings of Avoro Life Sciences Fund carry no return figures. PPLI Vortex estimates, from SEC filings: 10.6% in 2023, 16.7% in 2024, 41.6% in 2025, 16.9% in 2026 to 30 Jun. Each estimate has a range; for 2025 it is 18.3% to 64.9%.

How reliable are the return figures for Avoro Life Sciences Fund?

They are estimates, not figures reported by the fund. Each one is shown with a range and a grade. The grade for the latest figure is D-13F: estimated from the manager's Form 13F long book. Shorts, leverage, trading within a quarter and fees are not visible in public filings.

What does Avoro Life Sciences Fund invest in?

Avoro Life Sciences Fund does not publish its holdings. Its manager, Avoro Capital Advisors LLC, reported 26 U.S.-listed positions worth USD 11.1bn on Form 13F for 30 June 2026. The largest were UNITED THERAPEUTICS Corp, Ascendis Pharma A/S, Krystal Biotech, Inc. The filing covers all of the manager's accounts and excludes short positions.

How big is Avoro Life Sciences Fund?

Avoro Life Sciences Fund reported gross assets of USD 8.6bn in the Form ADV filed 4 June 2024. Gross assets are total assets before borrowings are deducted, so the figure is larger than what investors have put in when the fund uses leverage.

What is the minimum investment in Avoro Life Sciences Fund?

USD 1m, as stated in Form ADV Schedule D. The fund relies on the 3(c)(7) exclusion, so investors must be qualified purchasers. Managers can and do waive minimums.

Who audits and administers Avoro Life Sciences Fund?

The auditor is KPMG. The administrator is Hedgeserv (Cayman), Ltd. C/O Hedgeserv Corporation. These are the firms named in the Form ADV filed 4 June 2024.

Who runs Avoro Capital Advisors LLC?

On its own website Avoro Capital Advisors LLC names Behzad Aghazadeh (Managing Partner, Portfolio Manager). That is the list the firm gave when we read the site on 14 November 2026, and people move, so check with the firm.

When was Avoro Capital Advisors LLC founded?

In 2020, according to the firm's website. Its SEC registration is a separate date and is shown in the manager section of this page.

What does Avoro Capital Advisors LLC invest in?

On its website the firm writes mainly about healthcare and biotechnology and technology. That is how it describes itself, and it covers the whole firm, not Avoro Life Sciences Fund alone.

How do I contact Avoro Capital Advisors LLC?

The firm can be reached by email at [email protected], the details it gives on avorocapital.com. PPLI.com is not connected to the firm and cannot pass messages on.

Where is Avoro Capital Advisors LLC based?

Its website lists New York. The address on its SEC filing is in the manager section above.

Who manages Avoro Life Sciences Fund?

Avoro Capital Advisors LLC, CRD number 154091. It is an SEC-registered adviser.

Can Avoro Life Sciences Fund be held inside a PPLI policy?

Not directly, for a U.S. taxpayer. Under U.S. tax rules a policy reaches a hedge fund strategy through an insurance-dedicated fund or a separately managed account run for the insurer, not through a fund that is also sold to other investors. Policies issued outside the United States follow their own rules. We have no record that Avoro Capital Advisors LLC offers an insurance-dedicated version, so an investor would need to ask the firm.

What did Avoro Life Sciences Fund return each quarter?

Avoro Life Sciences Fund does not file quarterly returns with the SEC. PPLI Vortex estimates 19.7% in the third quarter of 2025, 14.9% in the fourth quarter of 2025, -0.1% in the first quarter of 2026 and 12.5% in the second quarter of 2026. Each figure has a range, shown on the page.

Next: how we work
Method and sources

How this page was put together

The return figures on this page come from PPLI Vortex, the engine we built to work out hedge fund returns from SEC filings. For this fund it takes the long positions the manager reports each quarter on Form 13F, prices them through the following quarter, and scales the result to how hedge funds with a similar footprint have behaved, using publicly reported returns as calibration. It is not the return the fund reports to its investors, which also reflects shorts, derivatives, cash, trading within the quarter and fees. Fund facts come from Form ADV Schedule D, section 7.B.(1), and from Form D. Apart from the short passage taken from the manager's public website and marked as such, nothing here comes from the fund or its manager.

Form ADV usedFiled 4 June 2024
Form D used1 May 2026
Public holder reports to30 June 2026
13F quarter30 June 2026
EnginePPLI Vortex v12.4
CorrectionsWrite to the editor

The full methodology

For the fund and its manager

Do you run Avoro Life Sciences Fund? Help us get it right.

If you manage this fund or work for Avoro Capital Advisors LLC, you can correct a fact, send us figures we do not have, such as audited returns, fees and terms, or point out a mistake. So can anyone else who spots one.

[email protected]

Please give the fund's name and its SEC private fund ID, 805-5609721763. We check what we receive against the filings, mark on the page what came from the manager, and publish any response you send, unedited.

Important information

Return figures on this page are estimates computed by PPLI.com from public regulatory filings using its PPLI Vortex engine. They are not reported, confirmed or audited by the fund, each is shown with a range and a confidence grade, and the true figures may differ materially from what investors received.

PPLI.com has no relationship with Avoro Life Sciences Fund or Avoro Capital Advisors LLC, and neither has reviewed or approved this page. Facts are taken from filings with the U.S. Securities and Exchange Commission as of the dates shown and may since have changed. Holdings come from the manager's Form 13F, which covers all of its accounts and omits short positions, so they are not a statement of what this fund owns.

Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy an interest in any fund or insurance policy. Interests in private funds are offered only to eligible investors, by the fund's own offering documents. Past performance, estimated or reported, does not predict future results. The calculators are illustrations built on assumptions you can change. To report an error, write to the editor.

Full legal name Avoro Life Sciences Fund LLCSEC private fund ID 805-5609721763Updated 15 November 2026
Private consultation →
Step 1 of 2

Tell us about yourself

Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.

✦Research assistant
✦PPLI.comResearch assistant
Explore PPLI questions and suitability factors
Ask a general question about PPLI, or explore the factors that affect suitability. Treat the answer as a starting point and check the linked sources.
Use the research with your own tax, legal and insurance advisers.
Preparing an answer
AI assistant. Educational information only. It does not determine eligibility or provide personal tax, legal, investment or insurance advice.